Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -241,598 | -149,421 | -132,774 | -93,767 | -176,937 |
| Depreciation Amortization | 113 | 62 | 34 | 15 | 49 |
| Accounts payable and accrued liabilities | -12,948 | -9,751 | -11,656 | -8,311 | 5,070 |
| Other Working Capital | -32,674 | -24,694 | -24,722 | -10,137 | 5,866 |
| Other Operating Activity | 128,543 | 62,721 | 60,537 | 57,598 | 24,734 |
| Operating Cash Flow | $-158,564 | $-121,083 | $-108,581 | $-54,602 | $-141,218 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -62,176 | N/A | N/A | N/A | N/A |
| PPE Investments | -672 | -669 | -594 | -385 | -24 |
| Investing Cash Flow | $-62,848 | $-669 | $-594 | $-385 | $-24 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 661,036 | 204,400 | 204,342 | 199,684 | 8,912 |
| Other Financing Activity | -1,529 | -1,504 | -1,504 | -1,504 | 0 |
| Financing Cash Flow | $659,507 | $202,896 | $202,838 | $198,180 | $8,912 |
| Exchange Rate Effect | -6,802 | 1,135 | -3,405 | -2,496 | 5,052 |
| Beginning Cash Position | 340,450 | 340,450 | 340,450 | 340,450 | 467,728 |
| End Cash Position | 771,743 | 422,729 | 430,708 | 481,147 | 340,450 |
| Net Cash Flow | $431,293 | $82,279 | $90,258 | $140,697 | $-127,278 |
| Free Cash Flow | |||||
| Operating Cash Flow | -158,564 | -121,083 | -108,581 | -54,602 | -141,218 |
| Capital Expenditure | -672 | -669 | -594 | -385 | -24 |
| Free Cash Flow | -159,236 | -121,752 | -109,175 | -54,987 | -141,242 |